IGF1 and acromegaly: While studies of the effect of pegvisomant on surrogate outcomes such as the IGF1 level are numerous, the impact of this GH receptor antagonist on comorbidities of acromegaly is poorly documented, despite health authorities' growing demands for hard endpoints.